Meeting
2023 ASCO Gastrointestinal Cancers Symposium
The efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors: A multicenter, retrospective study.
Authors
Weili Yang
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China;
Weili Yang , Haoran Qian , Litao Yang , Pengfei Wang , Hailong Qian , Binbin Chu , Zhuo Liu , Jingyu Sun , Dan Wu , Lifeng Sun , Wenqiang Zhou , Jingwei Hu , Xiaolei Chen , Chunhui Shou , Lingxiang Ruan , Jiren Yu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 800)
DOI
10.1200/JCO.2023.41.4_suppl.800
Abstract #
800
Poster Bd #
M15
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
KIT resistance mutations identified by circulating tumor DNA and treatment outcomes in advanced gastrointestinal stromal tumor.
First Author: Steven Bialick
Poster
2023 ASCO Annual Meeting
Clinical efficacy of avapritinib in gastrointestinal stromal tumors (GIST) with different KIT genotypes: Post hoc analysis of the phase 1 NAVIGATOR and phase 1/2 CS3007-101 trials.
First Author: Michael C. Heinrich
Poster
2020 ASCO Virtual Scientific Program
Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in ≥ fourth-line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.
First Author: Suzanne George
Poster
2020 Gastrointestinal Cancers Symposium
Clinical activity of avapritinib in ≥ fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST).
First Author: Michael C. Heinrich